Clinical trial
Safety Study of 188Re-PTI-6D2 in Patients With Metastatic Melanoma
NCT00399113 · Pain Therapeutics, Industry · Completed
Key facts
| NCT number | NCT00399113 |
|---|---|
| Title | Safety Study of 188Re-PTI-6D2 in Patients With Metastatic Melanoma |
| Official title | An Open-Label Phase I Safety, Pharmacokinetic & Dosimetry Study of 188Re-PTI-6D2 in Patients With Metastatic Melanoma |
| Lead sponsor | Pain Therapeutics, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Metastatic Melanoma |
| Intervention type | Drug |
| Interventions | 188Re-PTI-6D2 |
| Enrollment | 12 |
| Start date | May 1, 2007 |
| Primary completion | Jun 1, 2008 |
| First posted | Nov 14, 2006 |
| Last update posted | Jul 14, 2011 |
| Countries | Israel |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: